Nephrology really took an amazing turn this Kidney week in 2017. Positive trials, positive news and amazing things are happening for everyone involved in renal care.
First and foremost, the high impact clinical trials in 2017 ASN Kidney week revealed several positive trials.
The REPRISE study showed the impressive promise of use of tolvaptan in late stage ADPKD. The liver related side effects were minimal. Hope to see this in clinical practice soon
The MENTOR trial that compared cyclosporine to rituximab for PLA2R membranous GN showed rituximab to be non inferior with lower rate of adverse effects. Looks like rituximab will be changing the treatment paradigm in membranous GN treatment.
Is contrast nephropathy dead? No not really. A randomized controlled trial showed that intra arterial contrast studies are more likely to cause contrast nephropathy compared to intra-venous, but both did have a incidence of contrast nephropathy.
A novel agent called QPI-1002 showed significant promise in decreasing AKI post CABG in high risk population.
Bardoxolone Methyl Improved GFR Measured by Standard Inulin Clearance: The TSUBAKI Study in Japan. The return of Bard!!
Another positive note: The GW-ASN fellows survey showed an upswing in job opportunities for our fellows in training. https://www.asn-online.org/education/training/workforce/
Finally, social media nephrology Guru Joel Topf wins Robert Narins award with an amazing video presentation done by ASN.